Dr. Jänne’s Education
Dr. Pasi Jänne earned his M.D. and his Ph.D. from the University of Pennsylvania. He completed his internal medicine residency at the Brigham and Women’s Hospital and his oncology fellowship at Brigham’s Dana-Farber Cancer Institute.
Dr. Jänne currently practices as a medical oncologist at the Dana-Farber Cancer Institute, where he serves as Director for the Thoracic Oncology, Applied Cancer Science, and EGFR Mutant Lung Cancers programs. His special areas of interest include lung cancer and cancer drug resistance.
Dr. Pasi Jänne tests molecular targets to develop novel treatments for asbestos-related cancers.
Dr. Jänne works with a team of collaborators from 12 different countries. He is one of the co-discoverers of EGFR mutations in non-small cell lung cancer. Dr. Jänne focuses on understanding the mechanisms of drug-resistant lung cancer.
Along with his team of colleagues, Dr. Jänne tests molecular targets to develop novel treatments for asbestos-related cancers. He works to develop innovative treatment approaches, such as immunotherapy, photodynamic therapy, and intracavitary heat chemotherapy.
When facing a diagnosis of an asbestos-related cancer like lung cancer, it is crucial to find the right treatment right away. Contact Dr. Pasi Jänne today.